Background: Possible drug-drug interactions (DDIs) between antiretrovirals (ARVs) and direct-acting antiviral agents (DAAs) are of some concern.
Introduction
Direct-acting antiviral agents (DAAs) are highly effective for anti-HCV treatment in HIV/HCV coinfected patients, achieving cure rates of 91%-100% in clinical trials. 1, 2 Potential drug-drug interactions (DDIs) between antiretrovirals (ARVs) and DAAs are of concern, because of the shared metabolic pathway (cytochrome P450) 3 with two possible consequences: drug concentrations increasing or decreasing eventually leading, respectively, to toxicities or virological rebound. At present, clinicians are advised on treatment choice, [4] [5] [6] but most available information derive from studies in healthy volunteers or HIV/HCV coinfection trials. The clinical relevance of these results may be limited due to poor generalizability to the real-world setting. [7] [8] [9] Owing to possible DDIs, a significant proportion of patients need to change their ARVs before starting DAAs. Guidelines, 5, 6 publications 4, 10 and specific web sites (www.hep-druginteractions.org) state that ombitasvir/paritaprevir/ritonavir + dasabuvir (2D/3D) can be safely co-administered with NRTI or integrase inhibitors, while potential DDIs are predicted with NNRTIs and PIs. Sofosbuvir is the most suitable DAA for co-administration with commonly used ARVs, but some DDIs need to be considered. 10 Indeed, limited concurrent ARV options are allowed with simeprevir, ledipasvir, velpatasvir and daclatasvir. 2, 3 Our aim was to investigate the C trough for ARVs in the real-world setting of HIV/HCV coinfected subjects before and during a DAA regimen.
Patients and methods

Ethics
The study was conducted in accordance with the Declaration of Helsinki as well as with national and institutional standards. The local Ethics Committee approved the study protocol ('Banca Biologica del Fegato', approval reference number 20/2015). Patients entered the study after receiving the patient information and having given written informed consent (version 10, 3 February 2015) . All data were collected anonymously.
Study design
This study was a single-centre, prospective, observational study evaluating the C trough for ARVs in HIV/HCV coinfected persons undergoing anti-HCV treatment with DAAs at the National Institute for Infectious Diseases in Rome, Italy, between February 2015 and March 2016.
Study participants
A total of 137 HIV/HCV coinfected adults were included. HCV infection was assessed by HCV-RNA load determination and HCV genotyping. Transient elastography was used to measure stiffness and to classify fibrosis stages (F0-F4). Physicians prescribed DAAs according to anti-HCV treatment guidelines of the Italian Medicine Agency available during the study period (stage F3-F4 and any stage of fibrosis with HCV-associated extrahepatic manifestations), as well as within the Italian Expanded Access Program of 2D/3D for stage F2.
ARVs were chosen by physicians based on treatment history, HIV genotypic resistance testing, tolerability and recommendations for management of HCV/HIV coinfected persons in need of HCV treatment. [4] [5] [6] Regimens including ARVs contraindicated during DAAs were changed before DAAs start. The same ARVs were prescribed at the two timepoints: before DAAs (baseline) and during at least 2 months of anti-HCV treatment (during DAAs).
At these two timepoints, blood samples for ARV C trough measurements were collected. Viro-immunological parameters were assessed at baseline and monthly during DAA treatment. Patients filled a self-reported visual analogue scale (VAS) ranging from 0 (worst adherence) to 100 (best adherence) for assessment of ARV adherence at baseline and at 1 month of anti-HCV treatment. Data were abstracted anonymously from clinical charts.
ARV plasma concentrations
Venous blood samples for C trough levels were drawn at the end of dosing interval: 24 h " post-dose for drugs administered once daily and 12 h after the evening dose for drugs administered twice daily.
C trough was determined for each ARV of the regimen, except NRTIs, and measured using a validated HPLC-UV method, 11 which allowed for the simultaneous measurement of different drugs. The limit of quantification was 100 ng/mL for efavirenz, atazanavir and darunavir, and 50 ng/mL for raltegravir, dolutegravir, etravirine and rilpivirine. As suggested by Department of Health and Human Services (US) Guidelines, the minimum recommended target C trough values were extracted from a review on ARV therapeutic drug monitoring 12 and used to identify samples with suboptimal plasma concentrations (below the threshold).
Statistical analysis
Categorical variables were shown by frequency distributions and continuous variables by the mean and standard deviation or by the median and IQR.
The change of median C trough between samples collected before and during DAAs was estimated using all available measurements by a random effect linear regression model including an intercept (for the values before DAAs) and a slope (for the rate of change). This approach permits to use both paired and single measurements allowing a more precise and unbiased estimate of the variable of interest. Difference in median values was also calculated. Only C trough of ARVs carried out in more than five samples are shown. Statistical analyses were performed using STATA version 12.0.
Results
Patient population
The characteristics of the 137 HIV/HCV coinfected patients are shown in Table 1 . Twenty-nine patients (21.2%) received 2D/3D and 108 (78.8%) received sofosbuvir-based DAA. Sustained virological response for HCV infection was obtained in 94.1% of DAAtreated patients.
Concurrent ARV regimen was administered for a median of 19.9 months (IQR 4.07-44.77) and 43 patients (31.4%) needed to change their ARV drugs before DAAs to avoid DDIs. Besides NRTIs, patients could receive combinations of the following drugs: darunavir 800 mg once daily (together with ritonavir 100 mg in sofosbuvir-based regimens) (n " 39), raltegravir (n " 42), atazanavir/ritonavir (n " 29), rilpivirine (n " 19), etravirine (n " 13), efavirenz (n " 8), lopinavir/ritonavir (n " 5), fosamprenavir/ritonavir (n " 4), dolutegravir (n " 4) and elvitegravir/cobicistat (n " 3). Specific combinations of DAAs and ARVs are shown in Figure 1 .
At baseline, in all patients starting 2D/3D, HIV-RNA was ,40 copies/mL, whereas among subjects starting sofosbuvirbased DAA, HIV-RNA was detectable in nine cases (6.5%) with a median of 66 copies/mL (IQR 54-100).
Self-reported ARV adherence on the VAS was 93% (range 50-100) before anti-HCV treatment and 97% (range 75-100) during DAAs.
C trough of ARVs and HIV virological outcomes
Taken together before and during DAA treatment, the total number of samples available for C trough measurement of each ARV were 68 darunavir, 31 atazanavir, 8 lopinavir, 16 efavirenz, 21 etravirine, 32 rilpivirine, 74 raltegravir and 12 dolutegravir.
Suboptimal C trough before and during 2D/3D was found respectively in three (10.3%) (one darunavir, one raltegravir and one atazanavir) and three (10.3%) (two darunavir and one raltegravir) treated cases. In the sofosbuvir group, samples with suboptimal C trough were 16 (14.8%) and 11 (10.2%) involving miscellaneous ARV regimens. Figure 1 shows the median C trough values by specific ARVs and anti-HCV treatments, comparing samples collected before and during DAAs. In 2D/3D-treated patients, median darunavir C trough during DAAs was significantly lower than that observed before DAAs [1125 ng/mL (IQR 810-1616) versus 1903 ng/mL (IQR 1387-3983), respectively] (n " 5; P " 0.009), with a 40.9% decrease. Conversely, in the same group, comparison of median C trough of atazanavir and raltegravir did not show significant differences.
C trough of ARVs before and during DAA for HCV
JAC
In patients treated with sofosbuvir-based regimens, median C trough of ARVs was similar before and during DAA treatment.
Overall, we observed three HIV virological failures, 2 of 108 (1.9%) in the sofosbuvir group and 1 of 29 (3.5%) in the 2D/3D group. Notably, the latter was in one of the two patients with suboptimal darunavir C trough during 2D/3D treatment.
Discussion
In HIV/HCV coinfected patients the need for concurrent ARV and anti-HCV treatments hides the risk of DDIs and evidence from the real-world setting are lacking.
According to our analysis, 10% of blood samples collected during DAA treatment had a suboptimal plasma ARV concentration, even in a highly adherent population as assessed by selfreported VAS. Notably, this finding was not different from that observed in samples collected before starting DAA. Although the impact of this observation on HIV control may be negligible, it may deserve future investigation, as it has not been specifically addressed in our study.
When considering plasma concentrations of ARVs during DAAs, C trough of PIs during 2D/3D treatment were generally not different from those found before anti-HCV treatment. Although assessed in a small number of patients (n " 5), only the median C trough of darunavir (800 mg once daily) showed a significantly lower concentration during 2D/3D when compared with that found before DAAs. Similar to our findings, in a pharmacokinetic study conducted in healthy volunteers, co-administration of 3D and PIs was feasible and well tolerated, but authors described a 43%-48% reduction in darunavir and a 68% increase in atazanavir C trough levels. 13 Supporting the DDI between 2D/3D and darunavir, another study described a reduction in paritaprevir concentrations in HCV/HIV coinfected persons, compared with HCV mono-infected, and HCV treatment failure only in two coinfected patients on a darunavirbased ARV. The authors concluded that the PIs should be co-administered with a morning dose of 3D.
14 Based on these findings, it is possible that DDI between darunavir and 3D is doublefaceted with potential effects on both treatments. Reassuringly, our results comparing C trough of raltegravir did not show any significant differences before and during 2D/3D treatment, as observed in previous studies conducted among healthy volunteers. 15 Concerning DDI of sofosbuvir-based DAA treatments, they have shown a smaller impact on ARV plasma concentrations. 4 Indeed, we did not find differences in C trough before and during anti-HCV treatment for any ARV. This is in accordance with the fact that sofosbuvir is not a substrate of cytochrome P enzymes and no significant DDI with several ARVs have been found in healthy volunteers. 8 Even though our study has the key limitation of a relatively small number of blood samples in some ARV groups when stratified for type of DAA treatment, it may add some interesting information concerning the real-world setting. Because the smallest group was that of darunavir and 2D/3D, future studies on this issue are needed. Further limitations might be inter-and intra-personal variability of C trough and influence of other co-medications.
In conclusion, plasma concentrations of ARVs used during DAAs in a real-world population of HIV/HCV coinfected persons were generally not dissimilar from those found before anti-HCV treatment. Only darunavir showed a significant C trough reduction during 2D/3D treatment when compared with that found before. Measurement of ARV plasma concentrations during HCV treatment may give some useful information for the management of Tempestilli et al. 
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